About
Our Story
AlphaRose Therapeutics was founded by Casey McPherson, lead singer and song-writer, entrepreneur and father to Rose. As a baby, Rose was diagnosed with a rare genetic disease. Now eight years old, she has to face the world without words, scared by her seizures, unable to feed or take care of herself, and often alone.
Casey has been fighting for his daughter, and other children affected by genetic diseases, since 2016. He has become a leading voice in the rare disease field through his non-profit foundation To Cure A Rose Foundation, and Contract Research Organization, Everlum Bio.
In under a year, Casey and his science team successfully developed a preclinical treatment for his daughter’s disease. Throughout this journey, Casey identified a critical need for an innovative business model in the biotech and pharmaceutical sectors to ensure that their process could reach millions of children like Rose—an area that many other companies have overlooked. In 2024, he founded AlphaRose Therapeutics to address this gap.
Public-benefit corporation, AlphaRose Therapeutics, brings together Casey McPherson with industry leaders Belinda Termeer, Masako Nakamura, and Alan Walts, who worked alongside Henri Termeer at Genzyme in pioneering the field of rare disease biotech.
Together, they are building a precision medicine company to change how the industry develops and commercializes genetic disease treatments.
Our Mission
To develop and commercialize genetic treatments for suffering patients of small populations.
Our Vision
To make personalized medicine a reality for all patients and make therapies for rare genetic diseases common.
Meet the Team
-
Casey McPherson
FOUNDER & CEO
-
Belinda Termeer
CO-FOUNDER
-
Alan Walts, PhD
CO-FOUNDER & EXECUTIVE CHAIRMAN
-
Jeffrey Brown, PhD
HEAD OF R&D
-
Masako Nakamura
PRESIDENT & CHIEF OPERATING OFFICER
-
Robert Cabrera, PhD
CHIEF SCIENCE OFFICER